Medicine : Biotechnology and Chemical Inventions

Medicine

FTC Brushes Off Bristol's Attempt to Scrub Generic Competition
M. June Casalmir and Bernard Rhee of Bryan Cave LLP

On March 7, the FTC announced its settlement of claims against Bristol Myers Squibb ("Bristol") for employing patent listings in the FDA's "Orange Book" to delay the entry of generic competitors for three of Bristol's brand name pharmaceutical products. The settlement is the latest in a series of initiatives by the agency aimed at preventing misuse of Hatch-Waxman Act proceedings to forestall competition in the pharmaceutical marketsÂand yet another sign that protecting generic entry and expansion is serious business to the FTC.
Waxman-Hatch Law: What's Better For The Nation's Public Health, More Research Or Cheaper Generic Drugs?
Connolly Bove Lodge & Hutz LLP

The United States Patent Laws grant to a patentee the right to prevent others from.